183 related articles for article (PubMed ID: 33229301)
1. Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.
Riess JW; Frankel P; Shackelford D; Dunphy M; Badawi RD; Nardo L; Cherry SR; Lanza I; Reid J; Gonsalves WI; Kunos C; Gandara DR; Lara PN; Newman E; Paik PK
Clin Lung Cancer; 2021 Jan; 22(1):67-70. PubMed ID: 33229301
[TBL] [Abstract][Full Text] [Related]
2. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
Jeong Y; Hellyer JA; Stehr H; Hoang NT; Niu X; Das M; Padda SK; Ramchandran K; Neal JW; Wakelee H; Diehn M
Clin Cancer Res; 2020 Jan; 26(1):274-281. PubMed ID: 31548347
[TBL] [Abstract][Full Text] [Related]
3. Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
Paik PK; Fan PD; Qeriqi B; Namakydoust A; Daly B; Ahn L; Kim R; Plodkowski A; Ni A; Chang J; Fanaroff R; Ladanyi M; de Stanchina E; Rudin CM
J Thorac Oncol; 2023 Apr; 18(4):516-526. PubMed ID: 36240971
[TBL] [Abstract][Full Text] [Related]
4. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
Romero R; Sayin VI; Davidson SM; Bauer MR; Singh SX; LeBoeuf SE; Karakousi TR; Ellis DC; Bhutkar A; Sánchez-Rivera FJ; Subbaraj L; Martinez B; Bronson RT; Prigge JR; Schmidt EE; Thomas CJ; Goparaju C; Davies A; Dolgalev I; Heguy A; Allaj V; Poirier JT; Moreira AL; Rudin CM; Pass HI; Vander Heiden MG; Jacks T; Papagiannakopoulos T
Nat Med; 2017 Nov; 23(11):1362-1368. PubMed ID: 28967920
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Pathological Characteristics of
Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
[No Abstract] [Full Text] [Related]
6. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
[TBL] [Abstract][Full Text] [Related]
7. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
[TBL] [Abstract][Full Text] [Related]
8. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
9. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.
Gandara DR; Leighl N; Delord JP; Barlesi F; Bennouna J; Zalcman G; Infante JR; Reckamp KL; Kelly K; Shepherd FA; Mazieres J; Janku F; Gardner OS; Mookerjee B; Wu Y; Cox DS; Schramek D; Peddareddigari V; Liu Y; D'Amelio AM; Blumenschein G
J Thorac Oncol; 2017 Mar; 12(3):556-566. PubMed ID: 27876675
[TBL] [Abstract][Full Text] [Related]
10. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
Solis LM; Behrens C; Dong W; Suraokar M; Ozburn NC; Moran CA; Corvalan AH; Biswal S; Swisher SG; Bekele BN; Minna JD; Stewart DJ; Wistuba II
Clin Cancer Res; 2010 Jul; 16(14):3743-53. PubMed ID: 20534738
[TBL] [Abstract][Full Text] [Related]
11. A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.
Besse B; Barlesi F; Demedts I; Fuentes Pradera J; Robinet G; Gazzah A; Soldatenkova V; Frimodt-Moller B; Kim JS; Vansteenkiste J
Lung Cancer; 2019 Nov; 137():136-143. PubMed ID: 31586771
[TBL] [Abstract][Full Text] [Related]
12. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
Arbour KC; Jordan E; Kim HR; Dienstag J; Yu HA; Sanchez-Vega F; Lito P; Berger M; Solit DB; Hellmann M; Kris MG; Rudin CM; Ni A; Arcila M; Ladanyi M; Riely GJ
Clin Cancer Res; 2018 Jan; 24(2):334-340. PubMed ID: 29089357
[No Abstract] [Full Text] [Related]
13. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC.
Hellyer JA; Padda SK; Diehn M; Wakelee HA
J Thorac Oncol; 2021 Mar; 16(3):395-403. PubMed ID: 33307193
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Patel JD; Lee JW; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ; Das MS; Al-Nsour MA; Dakhil CSR; Ramalingam S; Schiller JH
Clin Lung Cancer; 2020 Nov; 21(6):520-526. PubMed ID: 32807654
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
[TBL] [Abstract][Full Text] [Related]
17. Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
Hellyer JA; Stehr H; Das M; Padda SK; Ramchandran K; Neal JW; Diehn M; Wakelee HA
Lung Cancer; 2019 Aug; 134():42-45. PubMed ID: 31319993
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Gerber DE; Camidge DR; Morgensztern D; Cetnar J; Kelly RJ; Ramalingam SS; Spigel DR; Jeong W; Scaglioni PP; Zhang S; Li M; Weaver DT; Vaikus L; Keegan M; Horobin JC; Burns TF
Lung Cancer; 2020 Jan; 139():60-67. PubMed ID: 31739184
[TBL] [Abstract][Full Text] [Related]
19. Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.
Zhang B; Ma Z; Tan B; Lin N
Expert Opin Ther Targets; 2019 Mar; 23(3):241-250. PubMed ID: 30556750
[TBL] [Abstract][Full Text] [Related]
20. KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub.
Scalera S; Mazzotta M; Cortile C; Krasniqi E; De Maria R; Cappuzzo F; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2022 Jun; 17(6):751-757. PubMed ID: 35351670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
